BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 16805946)

  • 1. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
    Murray M
    J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic drug interactions with newer antipsychotics: a comparative review.
    Spina E; de Leon J
    Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):4-22. PubMed ID: 17214606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomes.
    Daniel WA; Kot M; Wójcikowski J
    Pol J Pharmacol; 2003; 55(6):1055-61. PubMed ID: 14730101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of antipsychoatics.
    Ozaki N
    Nagoya J Med Sci; 2004 May; 67(1-2):1-7. PubMed ID: 15279062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.
    Shin JG; Soukhova N; Flockhart DA
    Drug Metab Dispos; 1999 Sep; 27(9):1078-84. PubMed ID: 10460810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and drug interactions: update for new antipsychotics.
    Ereshefsky L
    J Clin Psychiatry; 1996; 57 Suppl 11():12-25. PubMed ID: 8941167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
    Dahl ML
    Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of antipsychotics: useful for the clinician?
    Bondy B; Spellmann I
    Curr Opin Psychiatry; 2007 Mar; 20(2):126-30. PubMed ID: 17278909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic strategies for the personalization of antipsychotic treatment.
    Kerwin RW; Mancama DT; Arranz MJ
    Expert Rev Mol Diagn; 2001 Sep; 1(3):275-80. PubMed ID: 11901832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the genetic causes of inter-patient variability. Clinical relevance with focus on cardiovascular drugs.
    Ginghină C; Stănescu R; Coman IM; Bărbari L; Popescu BA
    Rom J Intern Med; 2007; 45(4):313-9. PubMed ID: 18767405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP-mediated clozapine interactions: how predictable are they?
    Chetty M; Murray M
    Curr Drug Metab; 2007 May; 8(4):307-13. PubMed ID: 17504220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical pharmacogenetics in the treatment of schizophrenia].
    Saito M; Yasui-Furukori N; Kaneko S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 polymorphisms and response to antipsychotic therapy.
    Scordo MG; Spina E
    Pharmacogenomics; 2002 Mar; 3(2):201-18. PubMed ID: 11972442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 enzymes and the heart.
    Chaudhary KR; Batchu SN; Seubert JM
    IUBMB Life; 2009 Oct; 61(10):954-60. PubMed ID: 19787709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.